Immediate Impact

8 from Science/Nature 54 standout
Sub-graph 1 of 19

Citing Papers

Multidrug-resistant Gram-negative bacterial infections
2025 Standout
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
2025 Standout
67 intermediate papers

Works of Christopher Lucasti being referenced

Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection
2016
Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections
2014
and 4 more

Author Peers

Author Last Decade Papers Cites
Christopher Lucasti 133 524 294 500 35 1.1k
Ómar Vesga 108 523 427 350 33 1.3k
Paul R. Ingram 66 349 386 368 61 1.4k
L. Leibovici 108 222 176 265 38 1.2k
Enrico Tagliaferri 59 339 260 584 35 1.1k
Elodie von Dach 75 350 164 201 35 1.0k
Matthew A. Wikler 391 328 263 306 21 1.4k
Cynthia L. Fowler 37 606 256 350 21 1.1k
Sorabh Dhar 79 232 216 430 55 894
Abrar K. Thabit 238 303 300 316 87 1.1k
Lance R. Peterson 97 186 633 224 30 1.2k

All Works

Loading papers...

Rankless by CCL
2026